Regulatory Intelligence

Regulatory intelligence helps organizations stay compliant and ahead of evolving drug safety requirements.

Role of Regulatory Intelligence

Regulatory Intelligence relates to the gathering, analyzing, and application of knowledge about regulatory updates to the ever-evolving requirements and guidelines relating to drug safety. Maintaining up- to- date knowledge of Regulatory Intelligence ensures that CROs and Pharmaceutical companies remain compliant with current reporting responsibilities, as well as surveillance requirements and risk management.

Regulatory Intelligence has many practical applications, including:

  • Regulatory Compliance
  • Drug Safety Monitoring
  • Market expansion
  • Crisis and/or Risk Management
  • Regulatory Audits and Inspections
  • Facilitating Market Access
Business worker holding espresso cup and stack of papers looking forward
Several business professionals having fun at a business meeting

Regulatory Intelligence at ProPharma

Regulatory Intelligence is a key pillar at ProPharma, and aims to simplify compliance, reduce risks, and ensure both ProPharma and our clients stay ahead of any regulatory changes. We achieve this by utilising various Regulatory Intelligence tools, Artificial Intelligence, completing monthly manual reviews of authority websites, as well as having a vast network of local knowledge to collect and evaluate local and global regulations.

The thorough analysis of any findings from each of these sources allows for an up-to-date Regulatory Intelligence Repository that colleagues can access to easily answer queries either internally or from clients. Where the answer isn’t already available, ProPharma has the ability to provide fast turnaround responses to ad-hoc requests for Regulatory Intelligence, going as far as offering one- to- one Regulatory Intelligence consultations.

Having access to the most up-to-date global regulation requirements, and the knowledge to interpret these regulations accurately, makes ProPharma completely qualified to perform submissions all over the world. This applies to periodic and expedited submissions, as well as Post-Marketing and Clinical Aggregate Report submissions, and EU product registration and updates in XEVMPD.

Our top priority at ProPharma is regulatory compliance, ensuring that all submissions are performed in accordance with applicable regulations. Due to our Regulatory Intelligence repository and expert interpretations of requirements, ProPharma is proud to consistently post a greater than 99% compliance rate for regulatory submissions, successfully submitting over 2,000 ICSRs per month to health authorities and ethics committees, and distributing reports on-time to investigators and business partners on behalf of our clients.

For clients utilizing our PV submission services, we offer access to the relevant RI for no additional cost, and for clients not utilizing our submissions services, we offer subscriptions to our PV RI information and updates. This information is provided in three different options that build upon each other, allowing the use of a single format or combination of formats. When you have needs, we have answers. Let us know how we can support you today.

Business professionals discussing data around a conference table

Regulatory Intelligence  Services

Stay ahead of regulatory changes with ProPharma's expert regulatory intelligence services. Contact us today to learn how we can support your compliance needs.

News & Insights

Building Relationships with Sites: The Hidden Driver of Faster Start-Ups

July 20, 2026

Building Relationships with Sites: The Hidden Driver of Faster Start-Ups

Discover effective strategies for building relationships with clinical trial sites to streamline the study start-up process and enhance activation timelines.

First Joint Clinical Assessments (JCAs): Key Lessons for EU HTA

July 14, 2026

First Joint Clinical Assessments (JCAs): Key Lessons for EU HTA

Learn what the first EU Joint Clinical Assessments reveal about evidence planning, PICO strategy, and HTA readiness for successful market access.

Turning Regulatory Complexity into Predictable Study Start-Up Execution

July 13, 2026

Turning Regulatory Complexity into Predictable Study Start-Up Execution

Explore how organizations can navigate regulatory complexity in clinical trials to achieve predictable study start-up timelines and operational excellence.

ProPharma Advances Technology Enablement Strategy with AI-Assisted Capability for ANDA Submission Development

July 8, 2026

ProPharma Advances Technology Enablement Strategy with AI-Assisted Capability fo...

ProPharma unveils an AI-assisted capability to enhance ANDA submission development, improving efficiency and maintaining regulatory excellence for clients.

ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and HTA Capabilities

June 18, 2026

ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and H...

ProPharma welcomes Kevin van Dooren as Vice President, HEOR and Market Access, strengthening integrated EU regulatory, HTA, reimbursement, and market access capabilities for life sciences companies.

ProPharma Appoints Adrian Pencak as Chief Commercial Officer

May 27, 2026

ProPharma Appoints Adrian Pencak as Chief Commercial Officer

ProPharma announces Adrian Pencak as Chief Commercial Officer, bringing 25 years of leadership experience to enhance global commercial capabilities and client partnerships.

ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Case Study Ensuring Continuity of Neonatal Vitamin Prophylaxis During a Product Shortage: A Regulatory and Pharmacovigilance-Led Solution - ProPharma

July 15, 2026

Ensuring Continuity of Neonatal Vitamin Prophylaxis During a Product Shortage: A...

Product shortages involving essential medicines can create significant clinical and regulatory challenges, particularly when vulnerable patient populations depend on uninterrupted access to...

Case Study Meeting Patients Where They Are: Delivering Global Clinical Support for Time-Sensitive Research - ProPharma

June 17, 2026

Meeting Patients Where They Are: Delivering Global Clinical Support for Time-Sen...

Conducting clinical research for rare pediatric populations presents unique operational challenges, particularly when eligible patients may be born anywhere in the world and require immediate...

Case Study Accelerating Commercial Readiness for a Novel Cell Therapy Program - ProPharma

June 10, 2026

Accelerating Commercial Readiness for a Novel Cell Therapy Program

As advanced therapy developers move from research-stage operations toward commercialization, they often face significant challenges in scaling quality systems, aligning regulatory strategy, and...

Tech Meets Touch: Evaluating Empathy and AI in Medical Information Delivery

June 4, 2026

Tech Meets Touch: Evaluating Empathy and AI in Medical Information Delivery

Artificial intelligence (AI) is a hot topic in Medical Information (MI), yet real-world evidence of its impact in regulated, human-led MI environments remains limited. Hear practical, evidence-based...

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

June 2, 2026

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

April 23, 2026

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...

News & Insights

Building Relationships with Sites: The Hidden Driver of Faster Start-Ups

July 20, 2026

Building Relationships with Sites: The Hidden Driver of Faster Start-Ups

Discover effective strategies for building relationships with clinical trial sites to streamline the study start-up process and enhance activation timelines.

First Joint Clinical Assessments (JCAs): Key Lessons for EU HTA

July 14, 2026

First Joint Clinical Assessments (JCAs): Key Lessons for EU HTA

Learn what the first EU Joint Clinical Assessments reveal about evidence planning, PICO strategy, and HTA readiness for successful market access.

Turning Regulatory Complexity into Predictable Study Start-Up Execution

July 13, 2026

Turning Regulatory Complexity into Predictable Study Start-Up Execution

Explore how organizations can navigate regulatory complexity in clinical trials to achieve predictable study start-up timelines and operational excellence.

Previous Post Arrow Next Post Arrow
ProPharma Advances Technology Enablement Strategy with AI-Assisted Capability for ANDA Submission Development

July 8, 2026

ProPharma Advances Technology Enablement Strategy with AI-Assisted Capability fo...

ProPharma unveils an AI-assisted capability to enhance ANDA submission development, improving efficiency and maintaining regulatory excellence for clients.

ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and HTA Capabilities

June 18, 2026

ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and H...

ProPharma welcomes Kevin van Dooren as Vice President, HEOR and Market Access, strengthening integrated EU regulatory, HTA, reimbursement, and market access capabilities for life sciences companies.

ProPharma Appoints Adrian Pencak as Chief Commercial Officer

May 27, 2026

ProPharma Appoints Adrian Pencak as Chief Commercial Officer

ProPharma announces Adrian Pencak as Chief Commercial Officer, bringing 25 years of leadership experience to enhance global commercial capabilities and client partnerships.

Previous Post Arrow Next Post Arrow
ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Previous Award Arrow Next Award Arrow
Case Study Ensuring Continuity of Neonatal Vitamin Prophylaxis During a Product Shortage: A Regulatory and Pharmacovigilance-Led Solution - ProPharma

July 15, 2026

Ensuring Continuity of Neonatal Vitamin Prophylaxis During a Product Shortage: A...

Product shortages involving essential medicines can create significant clinical and regulatory challenges, particularly when vulnerable patient populations depend on uninterrupted access to...

Case Study Meeting Patients Where They Are: Delivering Global Clinical Support for Time-Sensitive Research - ProPharma

June 17, 2026

Meeting Patients Where They Are: Delivering Global Clinical Support for Time-Sen...

Conducting clinical research for rare pediatric populations presents unique operational challenges, particularly when eligible patients may be born anywhere in the world and require immediate...

Case Study Accelerating Commercial Readiness for a Novel Cell Therapy Program - ProPharma

June 10, 2026

Accelerating Commercial Readiness for a Novel Cell Therapy Program

As advanced therapy developers move from research-stage operations toward commercialization, they often face significant challenges in scaling quality systems, aligning regulatory strategy, and...

Previous Resource Arrow Next Resource Arrow
Tech Meets Touch: Evaluating Empathy and AI in Medical Information Delivery

June 4, 2026

Tech Meets Touch: Evaluating Empathy and AI in Medical Information Delivery

Artificial intelligence (AI) is a hot topic in Medical Information (MI), yet real-world evidence of its impact in regulated, human-led MI environments remains limited. Hear practical, evidence-based...

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

June 2, 2026

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

April 23, 2026

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...

Previous Webinar Arrow Next Webinar Arrow